Cargando…

Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer

Breast cancer continues to be the most diagnosed cancer among women worldwide. Neoadjuvant chemotherapy is the standard of care for breast cancer patients with locally advanced disease and patients with poor pathological features, such as triple-negative (TN) or human epidermal growth factor recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Razeq, Hikmat, Khalil, Hanan, Assi, Hazem I., Dargham, Tarek Bou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406771/ https://www.ncbi.nlm.nih.gov/pubmed/36005196 http://dx.doi.org/10.3390/curroncol29080458

Ejemplares similares

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Surgical options for patients with early-stage breast cancer and pathogenic germline variants: an oncologist perspectives
por: Abdel-Razeq, Hikmat
Publicado: (2023)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2018)

Controversies of radiation therapy omission in elderly women with early stage invasive breast cancer
por: Abu-Gheida, Ibrahim, et al.
Publicado: (2020)

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2022)

Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2013)

Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve
por: Abdel-Razeq, Hikmat
Publicado: (2010)

Delays in Initiating Anti-Cancer Therapy for Early-Stage Breast Cancer—How Slow Can We Go?
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2023)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

Tumor characteristics and treatment outcomes of older patients with breast cancer in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
por: Horani, Malek, et al.
Publicado: (2023)

Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon
por: Atoui, Ali, et al.
Publicado: (2022)

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
por: Tfayli, Arafat, et al.
Publicado: (2020)

Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer
por: Abdel-Razeq, Hikmat
Publicado: (2019)

Inferior vena cava filters in cancer patients: to filter or not to filter
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study
por: Abdel-Razeq, Hikmat N., et al.
Publicado: (2020)

Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
por: Abdel-Razeq, Hikmat
Publicado: (2021)

Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Abdel-Razeq, Hikmat
Publicado: (2016)

Prolonged Neutropenia and Yellowish Discoloration of the Skin, But Not the Sclera, Following Excessive Turmeric Raw Root Ingestion
por: Abdel-Razeq, Rashid, et al.
Publicado: (2021)

Differences in clinicopathological characteristics, treatment, and survival outcomes between older and younger breast cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in long-distance travelers
por: Abdel-Razeq, Hikmat
Publicado: (2017)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2019)

Rates of Variants of Uncertain Significance Among Patients With Breast Cancer Undergoing Genetic Testing: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

Breast Cancer Care in Jordan
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2016)

Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
por: Al-Salam, Suhail, et al.
Publicado: (2019)

Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer
por: Almasri, Hanan, et al.
Publicado: (2022)

Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
por: Assi, Hazem I., et al.
Publicado: (2023)

Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
por: Marie, Lina, et al.
Publicado: (2022)

Metaplastic Breast Carcinoma: Experience of a Tertiary Cancer Center in the Middle East
por: Erjan, Ayah, et al.
Publicado: (2021)

The Application of Gail Model to Predict the Risk of Developing Breast Cancer among Jordanian Women
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m4gv2bltjc94jeqfm64sgb9hr5